Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05878288
Other study ID # HREC/88736/PMCC-2022-326880
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 26, 2023
Est. completion date May 2029

Study information

Verified date October 2023
Source Peter MacCallum Cancer Centre, Australia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.


Description:

The purpose of this study is to comprehensively assess the molecular profile of the tumour ecosystem of CSCC patients who receive immunotherapy in the neoadjuvant curative setting, in order to identify molecular mechanisms facilitating treatment response and resistance and to identify molecular markers for disease monitoring. Patients who receive immunotherapy for the neoadjuvant management of CSCC will be invited to participate in this translational research study during their treatment journey to provide tumour tissue (fresh and formal-fixed paraffin-embedded, FFPE) and blood samples before and after exposure to immunotherapy. This study has primarily a translational research objective with the clinical component conducted as a prospective, single-centre, single-arm, open label study.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 2029
Est. primary completion date May 2029
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Stage II to IV (M0) CSCC who are candidates for surgery, but who have an increased risk of recurrence and/or risk of disfigurement or loss of function. Patients with stage III or IV (M0) CSCC of the head/neck, extremity, or trunk are eligible, and patients with stage II CSCC (=3 cm longest diameter in an aesthetically sensitive region). 2. At least one measurable lesion per RECIST 1.1. 3. Age =18 years. 4. Histologically confirmed diagnosis of invasive CSCC. 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. 6. Anticipated life expectancy >12 weeks. 7. Adequate organ function defined as: i) Hepatic function: 1. Total bilirubin =1.5× upper limit of normal (ULN). 2. Patients with Gilbert's Disease and total bilirubin up to 3× ULN are eligible. 3. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) =3× ULN. 4. Alkaline phosphatase (ALP) =2.5× ULN. ii) Renal function: Serum creatinine =2× ULN or estimated creatinine clearance >35 mL/min (according the method of Cockcroft and Gault). iii) Creatinine phosphokinase (CPK) (also known as CK [creatinine kinase]) elevation = grade 2. iv) Bone marrow function: 1. Haemoglobin =9.0 g/dL. 2. Absolute neutrophil count (ANC) =1.5 x 109/L. 3. Platelet count =75 x 109/L. Exclusion Criteria: 1. Active solid malignancy or haematological malignancies including chronic lymphocytic leukaemia, (unless indolent or non-life-threatening) within the last 5 years. For clarity, exceptions include other non-melanoma skin cancer that has undergone potentially curative therapy, or in-situ cervical carcinoma or in-situ prostate cancer with non-detectable prostate specific antigen or any other tumour that has been treated, and the patient is deemed to be in complete remission for at least 2 years prior to enrolment. 2. Metastatic disease. 3. Steroid use >10mg prednisone per day within 14 days of study drug (except if physiologic replacement). 4. Active autoimmune disease requiring active systemic therapy within the last 5 years. 5. Interstitial lung disease or pneumonitis requiring systemic therapy in the last 5 years. 6. Active infection requiring therapy including human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV), or active tuberculosis. 7. Breast-feeding or positive serum pregnancy test consistent with pregnancy (excluding false positives defined as a failure of ßHCG doubling in 48 hours) or inability to comply with recommended contraception. 8. Receipt of live vaccine (including attenuated) within 30 days of first study treatment. 9. Prior transplant recipient (corneal transplant patients are eligible). 10. Prior PD-L1/PD-1 inhibitor exposure for the same lesion as enrolment. 11. Squamous cell carcinoma of unknown primary (those with presumed clinical assessment of CSCC are eligible). 12. Any anticancer treatment other than radiation therapy (such as chemotherapy, targeted systemic therapy, imiquimod, photodynamic therapy), either investigational or standard of care, within 30 days of the initial administration of cemiplimab or planned to occur during the study period. 13. History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments. 14. Patients with allergy or hypersensitivity to cemiplimab or to any of the excipients must be excluded. 15. Institutionalised patients by order of judicial or administrative authority. 16. Not willing to comply with all study related procedures, particularly consent for collection of tumour and blood samples and imaging, at all protocol specified time points.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cemiplimab
Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.

Locations

Country Name City State
Australia Peter MacCallum Cancer Centre Melbourne Victoria

Sponsors (6)

Lead Sponsor Collaborator
Peter MacCallum Cancer Centre, Australia Monash University, Regeneron Pharmaceuticals, Sanofi, University of Adelaide, University of Melbourne

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Other To describe any changes in the extent of surgical plans with the use of neoadjuvant immunotherapy, comparing plans at baseline and following neoadjuvant therapy. This outcome will be descriptive. Estimated 48months
Other Describe molecular mechanisms underlying resistance to immunotherapy in CSCC by comparing tumour and TME profiles from immunotherapy responders vs nonresponders defined using pathological response and CT imaging, to identify putative therapeutic targets. The outcome will be descriptive. 72 months
Other Describe whether genomic changes identified in CSCC and TME are detectable in cfDNA and whole blood, and whether these correlate with treatment response. 72 months
Other Describe molecular mechanisms underlying response to immunotherapy in CSCC by comparing tumour and TME profiles from immunotherapy responders vs nonresponders defined using pathological response and CT imaging, to identify putative predictive biomarkers. 72 months
Primary Rate of successful execution and generation of data from single-cell RNA sequencing and genomic profiling (including whole exome sequencing, RNA sequencing and immunohistochemistry) of CSCC from patients treated with immunotherapy Generation of analyzable data from single-cell RNA sequencing and genomic profiling At 72 months
Secondary To evaluate pathological response rates (cPR, mPR defined as <10% viable tumour, and other). Estimated 48 months
Secondary To evaluate ORR using computed tomography (CT) scan imaging assessed by RECIST 1.1 Estimated 48 months
Secondary To evaluate ORR using computed tomography (CT) scan imaging assessed by imRECIST Estimated 48 months
Secondary To summarise immune-related adverse events (AE) > grade 2, AESI, AEs > grade 3 and SAEs, according to CTCAE v5.0. At 72 months
Secondary To evaluate DFS rates. Estimated 48 months
Secondary To evaluate OS rates. Estimated 48 months
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Not yet recruiting NCT02806557 - Profiling Neutrophil Counts in Patients on Chemotherapy N/A